Feeds › Planned insider sales
Planned insider sales
Notices (SEC Form 144) that executives and other insiders file before selling shares, and whether a sale was reported afterwards.
About this data
- What it is
- Before an executive, director or large owner sells restricted or control shares, they file a short notice with the SEC, called Form 144, saying how many shares they plan to sell, through which broker and roughly when. This feed lists those notices, and for each one shows whether a sale was reported afterwards on a Form 4 and how many days later.
- Who files it
- The person selling, or their broker, on the day the sale is placed. Electronic notices start in April 2023.
- How current
- We collect new notices throughout the day on SEC business days.
- Terms
- Form 144The notice an insider or other affiliate of a company files with the SEC before selling restricted or control shares, so the shares can be sold under Rule 144. The notice says how many shares, through which broker, and roughly when.10b5-1 planA Rule 10b5-1 trading plan lets an insider set up future sales in advance, on a schedule or at set prices, at a time when they do not hold inside information. A notice that gives a plan adoption date says the sale is made under such a plan.
- Worth knowing
- A notice is a plan, not a sale: the person may sell fewer shares, later, or not at all. The value is the one the filer typed, at a price they chose, not what the shares sell for. Many sales are routine, made to diversify or pay taxes, or under a 10b5-1 plan set up months earlier. A blank in the last column does not mean no sale: the person may not have to file a Form 4 (an ordinary affiliate does not), the sale may be recent, or the Form 4 may name a different spelling of the person. We match by the filer's number first and by name second. Information, not investment advice.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Form 144 notices per day, last 30 days
All notices Notices that give a 10b5-1 plan
By the day each notice was filed. A notice is a plan to sell, not a sale.
Latest notices of planned insider sales
Showing: ticker EXPO
| Filed | Insider | Company | Shares to sellA notice is a plan, not a sale. The person may sell fewer shares, sell later, or not sell at all, and the number of shares is what they expect to sell on the day they file. | ValueThe aggregate market value the filer typed on the notice: the shares times a price the filer chose. It is not what the shares will sell for. | PlanA Rule 10b5-1 trading plan lets an insider set up future sales in advance, on a schedule or at set prices, at a time when they do not hold inside information. A notice that gives a plan adoption date says the sale is made under such a plan. | Expected sale | Sale reportedInsiders who are officers, directors or hold more than 10% report their sales on a Form 4, within two business days. We look for the first Form 4 with an open-market sale by the same person in the same company within 90 days of the notice, and show how many days after the notice it was filed. A blank means we found none: the person may not have sold, may not have to file a Form 4, or the Form 4 may be one we do not have. | Notice |
|---|---|---|---|---|---|---|---|---|
| Nov 3, 2026 | Richard Reiss Officer | EXPO Exponent, Inc. | 1,280 | $110.6K | — | Nov 3, 2026 | Form 4 ↗ 1 day later · 1,280 shares | Form 144 ↗ |
| Aug 17, 2026 | Catherine Corrigan Director, Officer | EXPO Exponent, Inc. | 1,707 | $114.5K | 10b5-1 | Aug 17, 2026 | Form 4 ↗ 1 day later · 1,707 shares | Form 144 ↗ |
| Jul 15, 2026 | Catherine Corrigan Director, Officer | EXPO Exponent, Inc. | 1,737 | $107.8K | 10b5-1 | Jul 15, 2026 | Form 4 ↗ 2 days later · 1,737 shares | Form 144 ↗ |
| Jun 15, 2026 | Catherine Corrigan Director, Officer | EXPO Exponent, Inc. | 4,119 | $235.1K | 10b5-1 | Jun 15, 2026 | Form 4 ↗ 2 days later · 4,119 shares | Form 144 ↗ |
| May 26, 2026 | Bradley Allyn James Officer | EXPO Exponent, Inc. | 2,000 | $114.9K | — | May 26, 2026 | Form 4 ↗ 1 day later · 2,000 shares | Form 144 ↗ |
| May 19, 2026 | Richard Reiss Officer | EXPO Exponent, Inc. | 1,672 | $98.1K | — | May 19, 2026 | Form 4 ↗ same day · 1,672 shares | Form 144 ↗ |
| May 15, 2026 | Catherine Corrigan Director, Officer | EXPO Exponent, Inc. | 4,194 | $225.1K | 10b5-1 | May 15, 2026 | Form 4 ↗ same day · 4,194 shares | Form 144 ↗ |
| May 13, 2026 | Joseph Rakow Officer | EXPO Exponent, Inc. | 2,945 | $161.0K | — | May 13, 2026 | Form 4 ↗ same day · 2,945 shares | Form 144 ↗ |
| May 13, 2026 | Joseph Sala Officer | EXPO Exponent, Inc. | 2,066 | $117.1K | — | May 13, 2026 | Form 4 ↗ same day · 2,066 shares | Form 144 ↗ |
| Apr 15, 2026 | Catherine Corrigan Director, Officer | EXPO Exponent, Inc. | 3,909 | $264.1K | 10b5-1 | Apr 15, 2026 | Form 4 ↗ 1 day later · 3,909 shares | Form 144 ↗ |
| Mar 16, 2026 | Catherine Corrigan Director, Officer | EXPO Exponent, Inc. | 3,912 | $263.6K | 10b5-1 | Mar 16, 2026 | Form 4 ↗ 31 days later · 7,821 shares | Form 144 ↗ |
| Feb 17, 2026 | Catherine Corrigan Director, Officer | EXPO Exponent, Inc. | 3,920 | $261.8K | 10b5-1 | Feb 17, 2026 | Form 4 ↗ 1 day later · 3,920 shares | Form 144 ↗ |
| Feb 10, 2026 | John Pye Officer | EXPO Exponent, Inc. | 4,000 | $303.9K | — | Feb 10, 2026 | Form 4 ↗ 2 days later · 4,000 shares | Form 144 ↗ |
| Jan 15, 2026 | Catherine Corrigan Director, Officer | EXPO Exponent, Inc. | 1,663 | $120.2K | 10b5-1 | Jan 15, 2026 | Form 4 ↗ 5 days later · 1,663 shares | Form 144 ↗ |
| Dec 15, 2025 | Catherine Corrigan Director, Officer | EXPO Exponent, Inc. | 3,225 | $237.5K | 10b5-1 | Dec 15, 2025 | Form 4 ↗ 1 day later · 3,225 shares | Form 144 ↗ |
| Nov 17, 2025 | Catherine Corrigan Director, Officer | EXPO Exponent, Inc. | 4,900 | $342.7K | 10b5-1 | Nov 17, 2025 | Form 4 ↗ 1 day later · 4,900 shares | Form 144 ↗ |
| Oct 15, 2025 | Catherine Corrigan Director, Officer | EXPO Exponent, Inc. | 4,930 | $330.0K | 10b5-1 | Oct 15, 2025 | Form 4 ↗ 1 day later · 4,930 shares | Form 144 ↗ |
| Sep 15, 2025 | Catherine Corrigan Director, Officer | EXPO Exponent, Inc. | 4,905 | $343.6K | 10b5-1 | Sep 15, 2025 | Form 4 ↗ 1 day later · 4,905 shares | Form 144 ↗ |
| Aug 14, 2025 | Catherine Corrigan Director, Officer | EXPO Exponent, Inc. | 4,896 | $355.7K | 10b5-1 | Aug 14, 2025 | Form 4 ↗ 1 day later · 4,896 shares | Form 144 ↗ |
| Aug 12, 2025 | Joseph Sala Officer | EXPO Exponent, Inc. | 1,595 | $112.7K | — | Aug 12, 2025 | Form 4 ↗ 1 day later · 1,595 shares | Form 144 ↗ |
| May 27, 2025 | Joseph Rakow Officer | EXPO Exponent, Inc. | 1,573 | $122.3K | — | May 27, 2025 | Form 4 ↗ same day · 1,573 shares | Form 144 ↗ |
| May 23, 2025 | John Pye Officer | EXPO Exponent, Inc. | 2,000 | $152.6K | — | May 23, 2025 | Form 4 ↗ same day · 2,000 shares | Form 144 ↗ |
| May 20, 2025 | Bradley A. James Officer | EXPO Exponent, Inc. | 2,694 | $214.2K | — | May 20, 2025 | Form 4 ↗ 1 day later · 2,694 shares | Form 144 ↗ |
| Feb 26, 2025 | Richard Reiss Officer | EXPO Exponent, Inc. | 1,736 | $149.2K | — | Feb 26, 2025 | Form 4 ↗ 1 day later · 1,736 shares | Form 144 ↗ |
| Nov 6, 2024 | Paul R Johnston Director | EXPO Exponent, Inc. | 42,000 | $4.1M | 10b5-1 | Nov 6, 2024 | Form 4 ↗ same day · 14,000 shares | Form 144 ↗ |
| Nov 4, 2024 | Carol Lindstrom Director | EXPO Exponent, Inc. | 1,039 | $100.1K | — | Nov 4, 2024 | Form 4 ↗ 1 day later · 1,039 shares | Form 144 ↗ |
| Jul 31, 2024 | Richard Reiss Officer | EXPO Exponent, Inc. | 2,206 | $237.1K | — | Jul 31, 2024 | — | Form 144 ↗ |
| Jul 30, 2024 | Richard L. Schlenker Jr. Officer | EXPO Exponent, Inc. | 98,314 | $10.4M | — | Jul 30, 2024 | — | Form 144 ↗ |
| Jul 30, 2024 | John Pye Officer | EXPO Exponent, Inc. | 3,956 | $415.4K | — | Jul 30, 2024 | — | Form 144 ↗ |
| Jul 30, 2024 | Carol Lindstrom Director | EXPO Exponent, Inc. | 932 | $99.9K | — | Jul 30, 2024 | — | Form 144 ↗ |
| May 23, 2024 | Paul R Johnston Director | EXPO Exponent, Inc. | 48,000 | $4.6M | 10b5-1 | May 23, 2024 | — | Form 144 ↗ |
| May 16, 2024 | Bradley A. James Officer | EXPO Exponent, Inc. | 2,030 | $193.3K | — | May 16, 2024 | — | Form 144 ↗ |
| May 7, 2024 | Joseph Rakow Officer | EXPO Exponent, Inc. | 1,971 | $187.2K | — | May 7, 2024 | — | Form 144 ↗ |
| May 2, 2024 | Bradley A. James Officer | EXPO Exponent, Inc. | 9,086 | $854.8K | — | May 2, 2024 | — | Form 144 ↗ |
| Apr 30, 2024 | Eric Guyer Officer | EXPO Exponent, Inc. | 3,496 | $323.7K | — | Apr 30, 2024 | — | Form 144 ↗ |
| Feb 9, 2024 | Eric Guyer Officer | EXPO Exponent, Inc. | 3,367 | $264.3K | — | Feb 9, 2024 | — | Form 144 ↗ |
| Nov 24, 2023 | Reitman Maureen T. F. Officer | EXPO Exponent, Inc. | 2,000 | $156.5K | — | Nov 24, 2023 | — | Form 144 ↗ |
| Aug 18, 2023 | Richard Reiss Officer | EXPO Exponent, Inc. | 856 | $75.2K | — | Aug 18, 2023 | — | Form 144 ↗ |
| Aug 4, 2023 | Steven J. Murray Officer | EXPO Exponent, Inc. | 2,000 | $179.0K | — | Aug 4, 2023 | — | Form 144 ↗ |
| May 24, 2023 | Richard Reiss Officer | EXPO Exponent, Inc. | 2,841 | $254.2K | — | May 24, 2023 | — | Form 144 ↗ |
| May 22, 2023 | Bradley A. James Officer | EXPO Exponent, Inc. | 1,500 | $134.0K | — | May 22, 2023 | — | Form 144 ↗ |
| May 11, 2023 | Joseph Rakow Officer | EXPO Exponent, Inc. | 1,388 | $120.2K | — | May 11, 2023 | — | Form 144 ↗ |
42 items, most recent first (up to 50). Every row links to the notice on the SEC's site, and to the Form 4 when we found one. Updated Nov 15, 2026, 6:46 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances